GUTS Stock Analysis: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.95
0.01 (0.60%)
▲
5d:
+27.52%
30d:
+76.67%
90d:
+132.29%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
14 traders called GUTS this week
92% bullish • 2 bearish
92% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: GUTS is 25.5% above its trading range ($0.76). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: GUTS is 25.5% above its trading range ($0.76). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.95, which is considered extended relative to its 30-day fair value range of $0.49 to $0.76.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.61, while resistance sits at $1.03.
Market Sentiment: GUTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.24 (+449.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.61, while resistance sits at $1.03.
Market Sentiment: GUTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.24 (+449.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.49 -
$0.76
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+25.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 449.3% below Wall St target ($5.24)
- WARNING: Recommendation downgraded due to 25.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.49 -
$0.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$1.03
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.38
Wall Street Target
$5.24
(+449.3%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: May 14, 2026 7:22 PM ET
Data refreshes hourly during market hours. Next update: 8:22 PM
Data refreshes hourly during market hours. Next update: 8:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Harith Rajagopalan
BUY
10416 shares
2025-12-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
